Contrast-enhanced MRI of murine myocardial infarction - Part I

NMR in Biomedicine

Volumn 25, Issue 8, 2012, Pages 953-968

  Geelen, Tessa ^a   Paulis, Leonie E M ^a   Coolen, Bram F ^a   Nicolay, Klaas ^a   Strijkers, Gustav J ^a  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

Cardiovascular MR (CMR) Methods; Gd chelate based contrast agents; Iron oxide based and other contrast agents; Ischemic heart diseases; Manganese enhanced MRI; Molecular and cellular probes

Indexed keywords

CARDIOVASCULAR MR (CMR) METHODS; CELLULAR PROBE; CONTRAST AGENT; ISCHEMIC HEART DISEASE; MANGANESE-ENHANCED MRI;

CARDIOLOGY; CELL DEATH; IMAGE ENHANCEMENT; IRON OXIDES; MANGANESE; PROBES; TISSUE; VISUALIZATION;

GADOLINIUM;

CELL ADHESION MOLECULE; COLLAGEN; CONTRAST MEDIUM; GADOLINIUM; LIPOCORTIN 5; MANGANESE; PHOSPHATIDYLSERINE;

ANGIOGENESIS; CELL DEATH; CELL VIABILITY; CONTRAST ENHANCEMENT; DISEASE COURSE; FIBROSIS; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; IN VIVO STUDY; INFLAMMATORY CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; CONTRAST MEDIA; GADOLINIUM; MAGNETIC RESONANCE IMAGING; MANGANESE; MICE; MYOCARDIAL INFARCTION; MYOCARDIUM;

MURINAE;

EID: 84863784379     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2768     Document Type: Review

References (142)

1. World Health Organization. Global status report on noncommunicable diseases 2010. Geneva, Switzerland 2010.
2. World Health Organization. World Health Statistics 2008. Geneva, Switzerland 2008.
3. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon J, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, De Korte CL, Aikawa M, Airaksinen KEJ, Assmann G, Becker C, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003; 108: 1664-1672.
4. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001; 104: 503-516.
5. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
6. Guyton AC, Hall JE. Textbook of Medical Physiology, 10th edn. W.B. Saunders Company: Philadelphia, USA, 2000.
7. Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail. Rev. 2011; 16: 13-21.
8. Sutton MGS, Sharpe N. Left ventricular remodeling after myocardial infarction - pathophysiology and therapy. Circulation 2000; 101: 2981-2988.
9. Cleutjens JP, Blankesteijn WM, Daemen MJ, Smits JF. The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc. Res. 1999; 44: 232-241.
10. Blankesteijn WM, Creemers E, Lutgens E, Cleutjens JP, Daemen MJ, Smits JF. Dynamics of cardiac wound healing following myocardial infarction: observations in genetically altered mice. Acta Physiol. Scand. 2001; 173: 75-82.
11. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc. Res. 2002; 53: 31-47.
12. Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid. Redox. Sign. 2006; 8: 1907-1939.
13. Michael LH, Entman ML, Hartley CJ, Youker KA, Zhu J, Hall SR, Hawkins HK, Berens K, Ballantyne CM. Myocardial ischemia and reperfusion: a murine model. Am. J. Physiol. 1995; 269: H2147-H2154.
14. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, De Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation 2011; 123: e18-e209.
15. Michael LH, Ballantyne CM, Zachariah JP, Gould KE, Pocius JS, Taffet GE, Hartley CJ, Pham TT, Daniel SL, Funk E, Entman ML. Myocardial infarction and remodeling in mice: effect of reperfusion. Am. J. Physiol. 1999; 277: H660-H668.
16. Lutgens E, Daemen MJ, De Muinck ED, Debets J, Leenders P, Smits JF. Chronic myocardial infarction in the mouse: cardiac structural and functional changes. Cardiovasc. Res. 1999; 41: 586-593.
17. De Celle T, Cleutjens JP, Blankesteijn WM, Debets JJ, Smits JF, Janssen BJ. Long-term structural and functional consequences of cardiac ischaemia-reperfusion injury in vivo in mice. Exp. Physiol. 2004; 89: 605-615.
18. Kumar D, Hacker TA, Buck J, Whitesell LF, Kaji EH, Douglas PS, Kamp TJ. Distinct mouse coronary anatomy and myocardial infarction consequent to ligation. Coronary Artery Dis. 2005; 16: 41-44.
19. Epstein FH. MR in mouse models of cardiac disease. NMR Biomed. 2007; 20: 238-255.
20. Bers DM. Cardiac excitation-contraction coupling. Nature 2002; 415: 198-205.
21. Bolli R, Marbán E. Molecular and cellular mechanisms of myocardial stunning. Physiol. Rev. 1999; 79: 609-634.
22. Anderson M. Mn ions pass through calcium channels: a possible explanation. J. Gen. Physiol. 1983; 81: 805-827.
23. Hunter DR, Haworth RA, Berkoff HA. Cellular manganese uptake by the isolated perfused rat heart: a probe for the sarcolemma calcium channel. J. Mol. Cell. Cardiol. 1981; 13: 823-832.
24. Zheng W, Kim H, Zhao Q. Comparative toxicokinetics of manganese chloride and methylcyclopentadienyl manganese tricarbonyl (MMT) in Sprague-Dawley rats. Toxicol. Sci. 2000; 54: 295-301.
25. 1 response to manganese injection in the dog and rabbit. Am. J. Roentgenol. 1983; 141: 193-197.
26. Bremerich J, Saeed M, Arheden H, Higgins CB, Wendland MF. Normal and infarcted myocardium: differentiation with cellular uptake of manganese at MR imaging in a rat model. Radiology 2000; 216: 524-530.
27. Saeed M, Wagner S, Wendland MF, Derugin N, Finkbeiner WE, Higgins CB. Occlusive and reperfused myocardial infarcts: differentiation with Mn-DPDP--enhanced MR imaging. Radiology 1989; 172: 59-64.
28. Skjold A, Amundsen BH, Wiseth R, Støylen A, Haraldseth O, Larsson HBW, Jynge P. Manganese dipyridoxyl-diphosphate (MnDPDP) as a viability marker in patients with myocardial infarction. J. Magn. Reson. Imaging 2007; 26: 720-727.
29. Hu TC-C, Bao W, Lenhard SC, Schaeffer TR, Yue T-L, Willette RN, Jucker BM. Simultaneous assessment of left-ventricular infarction size, function and tissue viability in a murine model of myocardial infarction by cardiac manganese-enhanced magnetic resonance imaging (MEMRI). NMR Biomed. 2004; 17: 620-626.
30. Delattre BMA, Braunersreuther V, Hyacinthe J-N, Crowe LA, Mach F, Vallée J-P. Myocardial infarction quantification with manganese-enhanced MRI (MEMRI) in mice using a 3T clinical scanner. NMR Biomed. 2010; 23: 503-513.
31. Lefrançois W, Miraux S, Calmettes G, Pourtau L, Franconi J-M, Diolez P, Thiaudière E. A fast black-blood sequence for four-dimensional cardiac manganese-enhanced MRI in mouse. NMR Biomed. 2011; 24: 291-298.
32. Delattre BMA, Braunersreuther V, Gardier S, Hyacinthe J-N, Crowe LA, Mach F, Vallée J-P. Manganese kinetics demonstrated double contrast in acute but not in chronic infarction in a mouse model of myocardial occlusion reperfusion. NMR Biomed. 2011; DOI:10.1002/nbm.1759
33. 1-mapping manganese-enhanced MRI in a murine model. NMR Biomed. 2009; 22: 874-881.
34. 1 mapping in rats. NMR Biomed. 2011; 24: 46-53.
35. 1-mapping cardiac manganese-enhanced MRI in a murine myocardial infarction model. NMR Biomed. 2008; 21: 1102-1111.
36. 1-mapping manganese-enhanced magnetic resonance imaging. Magn. Reson. Med. 2011; 65: 239-249.
37. Yang ZQ, Berr SS, Gilson WD, Toufektsian MC, French BA. Simultaneous evaluation of infarct size and cardiac function in intact mice by contrast-enhanced cardiac magnetic resonance imaging reveals contractile dysfunction in noninfarcted regions early after myocardial infarction. Circulation 2004; 109: 1161-1167.
38. 2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation 2004; 109: 2411-2416.
39. Weinmann HJ, Brasch RC, Press WR, Wesbey GE. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am. J. Roentgenol. 1984; 142: 619-624.
40. Port M, Idée J-M, Medina C, Robic C, Sabatou M, Corot C. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 2008; 21: 469-490.
41. Oshinski JN, Yang Z, Jones JR, Mata JF, French BA. Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging. Circulation 2001; 104: 2838-2842.
42. Klein C, Nekolla SG, Balbach T, Schnackenburg B, Nagel E, Fleck E, Schwaiger M. The influence of myocardial blood flow and volume of distribution on late Gd-DTPA kinetics in ischemic heart failure. J. Magn. Reson. Imaging 2004; 20: 588-594.
43. Saeed M. New concepts in characterization of ischemically injured myocardium by MRI. Exp. Biol. Med. 2001; 226: 367-376.
44. Wang Y, Sun W, Cao GA, Meng LA, Song LF, Du XK. Delayed hyperenhancement patterns in occlusive and reperfused myocardial infarcts during different healing stages. J. Magn. Reson. Imaging 2006; 24: 851-857.
45. Wesbey GE, Higgins CB, McNamara MT, Engelstad BL, Lipton MJ, Sievers R, Ehman RL, Lovin J, Brasch RC. Effect of gadolinium-DTPA on the magnetic relaxation times of normal and infarcted myocardium. Radiology 1984; 153: 165-169.
46. Ojha N, Roy S, Radtke J, Simonetti O, Gnyawali S, Zweier JL, Kuppusamy P, Sen CK. Characterization of the structural and functional changes in the myocardium following focal ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2008; 294: H2435-H2443.
47. Protti A, Sirker A, Shah AM, Botnar R. Late gadolinium enhancement of acute myocardial infarction in mice at 7T: cine-FLASH versus inversion recovery. J. Magn. Reson. Imaging 2010; 32: 878-886.
48. Bohl S, Lygate CA, Barnes H, Medway D, Stork L-A, Schulz-Menger J, Neubauer S, Schneider JE. Advanced methods for quantification of infarct size in mice using three-dimensional high-field late gadolinium enhancement MRI. Am. J. Physiol. Heart Circ. Physiol. 2009; 296: H1200-H1208.
49. French BA, Beyers RJ, Sureau FC, Yang Z, Gilson WD, Roy RJ, Berr SS, Epstein FH. Imaging infarct expansion in mice using a contrast-enhanced inversion recovery MRI sequence. J. Cardiovasc. Magn. Reson. 2005; 7: 172-173.
50. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999; 100: 1992-2002.
51. Saeed M, Lund G, Wendland MF, Bremerich J, Weinmann H, Higgins CB. Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction with necrosis-specific and extracellular nonspecific contrast media. Circulation 2001; 103: 871-876.
52. Amado LC, Gerber BL, Gupta SN, Rettmann DW, Szarf G, Schock R, Nasir K, Kraitchman DL, Lima JAC. Accurate and objective infarct sizing by contrast-enhanced magnetic resonance imaging in a canine myocardial infarction model. J. Am. Coll. Cardiol. 2004; 44: 2383-2389.
53. Hsu L-Y, Natanzon A, Kellman P, Hirsch GA, Aletras AH, Arai AE. Quantitative myocardial infarction on delayed enhancement MRI. Part I: animal validation of an automated feature analysis and combined thresholding infarct sizing algorithm. J. Magn. Reson. Imaging 2006; 23: 298-308.
54. Schmiedl U, Sievers RE, Brasch RC, Wolfe CL, Chew WM, Ogan MD, Engeseth H, Lipton MJ, Moseley ME. Acute myocardial ischemia and reperfusion: MR imaging with albumin-Gd-DTPA. Radiology 1989; 170: 351-356.
55. Bremerich J, Wendland MF, Arheden H, Wyttenbach R, Gao DW, Huberty JP, Dae MW, Higgins CB, Saeed M. Microvascular injury in reperfused infarcted myocardium: noninvasive assessment with contrast-enhanced echoplanar magnetic resonance imaging. J. Am. Coll. Cardiol. 1998; 32: 787-793.
56. Geelen T, Paulis LE, Coolen BF, Nicolay K, Strijkers GJ. Passive targeting of paramagnetic lipid-based contrast agents to acute mouse cardiac ischemia/reperfusion injury. Proceedings of the 19th Annual Meeting ISMRM, Montreal, Canada, 2011; 1356.
57. Paulis LE, Geelen T, Kuhlmann MT, Coolen BF, Nicolay K, Strijkers GJ. Contrast-enhanced cardiac MRI of vascular remodeling after myocardial infarction using lipid-based nanoparticles. Proceedings of the 19th Annual Meeting ISMRM, Montreal, Canada, 2011; 1358.
58. 1 mapping of the mouse heart using variable flip angle steady-state MR imaging. NMR Biomed. 2011; 24: 154-162.
59. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Brit. J. Cancer. 1972; 26: 239-257.
60. Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr. Opin. Cell Biol. 2004; 16: 663-669.
61. Kaminski KA, Bonda TA, Korecki J, Musial WJ. Oxidative stress and neutrophil activation - the two keystones of ischemia/reperfusion injury. Int. J. Cardiol. 2002; 86: 41-59.
62. Buja LM. Myocardial ischemia and reperfusion injury. Cardiovasc. Pathol. 2005; 14: 170-175.
63. Zhao ZQ. Oxidative stress-elicited myocardial apoptosis during reperfusion. Curr. Opin. Pharmacol. 2004; 4: 159-165.
64. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J. Clin. Invest. 1994; 94: 1621-1628.
65. Zhao ZQ, Velez DA, Wang NP, Hewan-Lowe KO, Nakamura M, Guyton RA, Vinten-Johansen J. Progressively developed myocardial apoptotic cell death during late phase of reperfusion. Apoptosis 2001; 6: 279-290.
66. Takashi E, Ashraf M. Pathologic assessment of myocardial cell necrosis and apoptosis after ischemia and reperfusion with molecular and morphological markers. J. Mol. Cell. Cardiol. 2000; 32: 209-224.
67. Cheng W, Kajstura J, Nitahara JA, Li B, Reiss K, Liu Y, Clark WA, Krajewski S, Reed JC, Olivetti G, Anversa P. Programmed myocyte cell death affects the viable myocardium after infarction in rats. Exp. Cell Res. 1996; 226: 316-327.
68. Freude B, Masters TN, Robicsek F, Fokin A, Kostin S, Zimmermann R, Ullmann C, Lorenz-Meyer S, Schaper J. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J. Mol. Cell. Cardiol. 2000; 32: 197-208.
69. Fliss H, Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ. Res. 1996; 79: 949-956.
70. McCully JD, Wakiyama H, Hsieh YJ, Jones M, Levitsky S. Differential contribution of necrosis and apoptosis in myocardial ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2004; 286: H1923-H1935.
71. Boersma HH, Kietselaer B, Stolk LML, Bennaghmouch A, Hofstra L, Narula J, Heidendal GAK, Reutelingsperger CPM. Past, present, and future of annexin A5: From protein discovery to clinical applications. J. Nucl. Med. 2005; 46: 2035-2050.
72. Schellenberger EA, Sosnovik D, Weissleder R, Josephson L. Magneto/optical annexin V, a multimodal protein. Bioconjug. Chem. 2004; 15: 1062-1067.
73. Sosnovik DE, Schellenberger EA, Nahrendorf M, Novikov MS, Matsui T, Dai G, Reynolds F, Grazette L, Rosenzweig A, Weissleder R, Josephson L. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn. Reson. Med. 2005; 54: 718-724.
74. Sosnovik DE, Garanger E, Aikawa E, Nahrendorf M, Figuiredo J-L, Dai G, Reynolds F, Rosenzweig A, Weissleder R, Josephson L. Molecular MRI of cardiomyocyte apoptosis with simultaneous delayed-enhancement MRI distinguishes apoptotic and necrotic myocytes in vivo: potential for midmyocardial salvage in acute ischemia. Circ. Cardiovasc. Imaging 2009; 2: 460-467.
75. Chen HH, Josephson L, Sosnovik DE. Imaging of apoptosis in the heart with nanoparticle technology. WIREs Nanomed. Nanobiotechnol. 2011; 3: 86-99.
76. van Tilborg GAF, Mulder WJM, Deckers N, Storm G, Reutelingsperger CPM, Strijkers GJ, Nicolay K. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjug. Chem. 2006; 17: 741-749.
77. Geelen T, Paulis LEM, van Tilborg GAF, Reutelingsperger CPM, Nicolay K, Strijkers GJ. Towards in vivo MR imaging of apoptotic myocardium after ischemia/reperfusion injury. Magn. Reson. Mater. Phy. 2009; 22: S1-251.
78. Garanger E, Hilderbrand SA, Blois JT, Sosnovik DE, Weissleder R, Josephson L. A DNA-binding Gd chelate for the detection of cell death by MRI. Chem. Commun. 2009; 7: 4444-4446.
79. Huang S, Chen HH, Yuan H, Dai G, Schuhle DT, Mekkaoui C, Ngoy S, Liao R, Caravan P, Josephson L, Sosnovik DE. Molecular MRI of acute necrosis with a novel DNA-binding gadolinium chelate: kinetics of cell death and clearance in infarcted myocardium. Circ. Cardiovasc. Imaging 2011; 4(6): 729-737.
80. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006; 114: 1504-1511.
81. Hoyte LC, Brooks KJ, Nagel S, Akhtar A, Chen R, Mardiguian S, Mcateer MA, Anthony DC, Choudhury RP, Buchan AM, Sibson NR. Molecular magnetic resonance imaging of acute vascular cell adhesion molecule-1 expression in a mouse model of cerebral ischemia. J. Cerebr. Blood. F. Met. 2010; 30: 1178-1187.
82. Jin AY, Tuor UI, Rushforth D, Filfil R, Kaur J, Ni F, Tomanek B, Barber PA. Magnetic resonance molecular imaging of post-stroke neuroinflammation with a P-selectin targeted iron oxide nanoparticle. Contrast Media Mol. Imaging. 2009; 4: 305-311.
83. van Bochove GS, Chatrou ML, Paulis LE, Grull H, Strijkers GJ, Nicolay K. VCAM-1 targeted MRI for imaging of inflammation in mouse atherosclerosis using paramagnetic and superparamagnetic lipid-based contrast agents. Proceedings of the 18th Annual Meeting ISMRM, Stockholm, Sweden, 2010; 1258.
84. Dall'Armellina E, Lygate CA, Mcateer M, Bohl S, Stork L-A, Neubauer S, Choudhury RP, Schneider JE. Ex vivo and in vivo MR imaging of ischemia reperfusion injury in mouse hearts using microparticles of iron oxide targeting VCAM-1. Proceedings of the 18th Annual Meeting ISMRM, Stockholm, Sweden, 2010; 3637.
85. Paulis LE, Jacobs I, van den Akker NM, Coolen BF, Geelen T, Nicolay K, Strijkers GJ. In vivo molecular MRI of ICAM-1 expression in murine cardiac ischemia/reperfusion using a liposomal nanoparticle. Proceedings of the 19th Annual Meeting ISMRM, Montreal, Canada, 2011; 1660.
86. Mcateer MA, Sibson NR, Von Zur Muhlen C, Schneider JE, Lowe AS, Warrick N, Channon KM, Anthony DC, Choudhury RP. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat. Med. 2007; 13: 1253-1258.
87. Akhtar AM, Schneider JE, Chapman SJ, Jefferson A, Digby JE, Mankia K, Chen Y, Mcateer MA, Wood KJ, Choudhury RP. In vivo quantification of VCAM-1 expression in renal ischemia reperfusion injury using non-invasive magnetic resonance molecular imaging. PLoS One 2010; 5(9): e12800.
88. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo J-L, Libby P, Weissleder R, Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 2007; 204: 3037-3047.
89. Saleh A, Wiedermann D, Schroeter M, Jonkmanns C, Jander S, Hoehn M. Central nervous system inflammatory response after cerebral infarction as detected by magnetic resonance imaging. NMR Biomed. 2004; 17: 163-169.
90. Henning EC, Ruetzler CA, Gaudinski MR, Hu TC-C, Latour LL, Hallenbeck JM, Warach S. Feridex preloading permits tracking of CNS-resident macrophages following transient middle cerebral artery occlusion. J. Cerebr. Blood F. Met. 2009; 29: 1229-1239.
91. Jaffer FA, Nahrendorf M, Sosnovik D, Kelly KA, Aikawa E, Weissleder R. Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials. Mol. Imaging 2006; 5: 85-92.
92. Yang Y, Yang Y, Yanasak N, Schumacher A, Hu TC-C. Temporal and noninvasive monitoring of inflammatory-cell infiltration to myocardial infarction sites using micrometer-sized iron oxide particles. Magn. Reson. Med. 2010; 63: 33-40.
93. Yang Y, Liu J, Yang Y, Cho SH, Hu TC. Assessment of cell infiltration in myocardial infarction: a dose-dependent study using micrometer-sized iron oxide particles. Magn. Reson. Med. 2011; 66(5): 1353-1361.
94. Protti A, Dong X, Andia M, Chaubey S, Yu B, Taupitz M, Botnar RM, Shah A. Imaging of inflammation using VSOP at multiple time points in a mouse model of myocardial infarction. Proceedings of the 19th Annual Meeting ISMRM, Montreal, Canada, 2011; 3409.
95. Vandervelde S, van Amerongen MJ, Tio RA, Petersen AH, van Luyn MJA, Harmsen MC. Increased inflammatory response and neovascularization in reperfused vs. nonreperfused murine myocardial infarction. Cardiovasc. Pathol. 2006; 15: 83-90.
96. Matuszewski L, Persigehl T, Wall A, Schwindt W, Tombach B, Fobker M, Poremba C, Ebert W, Heindel W, Bremer C. Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling Efficiency. Radiology 2005; 235: 155-161.
97. Shapiro EM, Skrtic S, Sharer K, Hill JM, Dunbar CE, Koretsky AP. MRI detection of single particles for cellular imaging. P. Natl Acad. Sci. USA 2004; 101: 10901-10906.
98. Sosnovik DE, Nahrendorf M, Deliolanis N, Novikov M, Aikawa E, Josephson L, Rosenzweig A, Weissleder R, Ntziachristos V. Fluorescence tomography and magnetic resonance imaging of myocardial macrophage infiltration in infarcted myocardium in vivo. Circulation 2007; 115: 1384-1391.
99. Nahrendorf M, Sosnovik DE, Waterman P, Swirski FK, Pande AN, Aikawa E, Figueiredo J-L, Pittet MJ, Weissleder R. Dual channel optical tomographic imaging of leukocyte recruitment and protease activity in the healing myocardial infarct. Circ. Res. 2007; 100: 1218-1225.
100. hi monocytosis. J. Am. Coll. Cardiol. 2010; 55: 1629-1638.
101. 1-mapping. Proceedings of the 19th Annual Meeting ISMRM, Montreal, Canada, 2011; 1355.
102. Geelen T, Yeo SY, Paulis LE, Coolen BF, Nicolay K, Strijkers GJ. In vivo MR imaging of macrophages in cardiac ischemia/reperfusion injury with paramagnetic phosphatidylserine-containing liposomes. Proceedings of the 19th Annual Meeting ISMRM, Montreal, Canada, 2011; 323.
103. Flogel U, Ding Z, Hardung H, Jander S, Reichmann G, Jacoby C, Schubert R, Schrader J. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation 2008; 118: 140-148.
104. Brennan M-L, Hazen SL. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr. Opin. Lipidol. 2003; 14: 353-359.
105. Querol M, Chen JW, Weissleder R, Bogdanov AJ. DTPA-bisamide-based MR sensor agents for peroxidase imaging. Org. Lett. 2005; 7: 1719-1722.
106. Nahrendorf M, Sosnovik D, Chen JW, Panizzi P, Figueiredo J-L, Aikawa E, Libby P, Swirski FK, Weissleder R. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation 2008; 117: 1153-1160.
107. 3-integrin targeted multimodal quantum dots. Angiogenesis 2009; 12: 17-24.
108. Mulder WJM, Strijkers GJ, Habets JW, Bleeker EJW, van der Schaft DWJ, Storm G, Koning GA, Griffioen AW, Nicolay K. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J. 2005; 19: 2008-2010.
109. 3-targeted nanoparticle and 1.5 Tesla magnetic resonance imaging. Cancer Res. 2003; 63: 5838-5843.
110. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-380.
111. Buehler A, van Zandvoort M, Stelt BJ, Hackeng TM, Schrans-Stassen B, Bennaghmouch A, Hofstra L, Cleutjens JPM, Duijvestijn A, Smeets MB, de Kleijn DPV, Post MJ, de Muinck ED. cNGR: A novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo. Arterioscl. Throm. Vas. 2006; 26: 2681-2687.
112. Oostendorp M, Douma K, Wagenaar A, Slenter JMGM, Hackeng TM, van Zandvoort MAMJ, Post MJ, Backes WH. Molecular magnetic resonance imaging of myocardial angiogenesis after acute myocardial infarction. Circulation 2010; 121: 775-783.
113. 2 mapping. Magn. Reson. Med. 2010; 64: 291-298.
114. Oostendorp M, Douma K, Hackeng TM, Dirksen A, Post MJ, Van Zandvoort MAMJ, Backes WH. Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGR-labeled paramagnetic quantum dots. Cancer Res. 2008; 68: 7676-7683.
115. Caravan P, Das B, Dumas S, Epstein FH, Helm PA, Jacques V, Koerner S, Kolodziej A, Shen L, Sun W-C, Zhang Z. Collagen-targeted MRI contrast agent for molecular imaging of fibrosis. Angew Chem. Int. Ed. Engl. 2007; 46: 8171-8173.
116. Helm PA, Caravan P, French BA, Jacques V, Shen L, Xu Y, Beyers RJ, Roy RJ, Kramer CM, Epstein FH. Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Radiology 2008; 247: 788-796.
117. Paulis LE, Klein A, Geelen T, Fleischmann BK, Roell W, Nicolay K, Strijkers GJ. Embryonic cardiomyocytes improve contractility and viability of ischemic myocardium. Proceedings of the 19th Annual Meeting ISMRM, Montreal, Canada, 2011; 16.
118. van Bochove GS, Paulis LEM, Segers D, Mulder WJM, Krams R, Nicolay K, Strijkers GJ. Contrast enhancement by differently sized paramagnetic MRI contrast agents in mice with two phenotypes of atherosclerotic plaque. Contrast Media Mol. Imaging 2011; 6: 35-45.
119. 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla. Invest. Radiol. 2006; 41: 305-312.
120. 13C MRI. Magn. Reson. Med. 2008; 59: 1005-1013.
121. Kramer CM, Sinusas AJ, Sosnovik DE, French BA, Bengel FM. Multimodality imaging of myocardial injury and remodeling. J. Nucl. Med. 2010; 51: 107S-121S.
122. Davis SC, Pogue BW, Springett R, Leussler C, Mazurkewitz P, Tuttle SB, Gibbs-Strauss SL, Jiang SS, Dehghani H, Paulsen KD. Magnetic resonance-coupled fluorescence tomography scanner for molecular imaging of tissue. Rev. Sci. Instrum. 2008; 79(6): 064302.
123. 3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc. Res. 2008; 78: 395-403.
124. Stegger L, Schafers K, Kopka K, Wagner S, Hermann S, Kies P, Law M, Schober O, Schafers M. Molecular cardiovascular imaging using scintigraphic methods. Eur. Radiol. 2007; 17: 1422-1432.
125. Berr SS, Xu Y, Roy RJ, Kundu B, Williams MB, French BA. Serial multimodality assessment of myocardial infarction in mice using magnetic resonance imaging and micro-positron emission tomography provides complementary information on the progression of scar formation. Circulation 2007; 115: e428-e429.
126. Thomas D, Bal H, Arkles J, Horowitz J, Araujo L, Acton PD, Ferrari VA. Noninvasive assessment of myocardial viability in a small animal model: comparison of MRI, SPECT, and PET. Magn. Reson. Med. 2008; 59: 252-259.
127. Nahrendorf M, Aikawa E, Figueiredo J-L, Stangenberg L, Van Den Borne SW, Blankesteijn WM, Sosnovik DE, Jaffer FA, Tung C-H, Weissleder R. Transglutaminase activity in acute infarcts predicts healing outcome and left ventricular remodelling: implications for FXIII therapy and antithrombin use in myocardial infarction. Eur. Heart J. 2008; 29: 445-454.
128. Meoli DF, Sadeghi MM, Krassilnikova S, Bourke BN, Giordano FJ, Dione DP, Su HL, Edwards DS, Liu S, Harris TD, Madri JA, Zaret BL, Sinusas AJ. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J. Clin. Invest. 2004; 113: 1684-1691.
129. Su H, Spinale FG, Dobrucki LW, Song J, Hua J, Sweterlitsch S, Dione DP, Cavaliere P, Chow C, Bourke BN, Hu X-Y, Azure M, Yalamanchili P, Liu R, Cheesman EH, Robinson S, Edwards DS, Sinusas AJ. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 2005; 112: 3157-3167.
130. Verjans JWH, Lovhaug D, Narula N, Petrov AD, Indrevoll B, Bjurgert E, Krasieva TB, Petersen LB, Kindberg GM, Solbakken M, Cuthbertson A, Vannan MA, Reutelingsperger CPM, Tromberg BJ, Hofstra L, Narula J. Noninvasive imaging of angiotensin receptors after myocardial infarction. J. Am. Coll. Cardiol. Cardiovasc. Imaging. 2008; 1: 354-362.
131. Pichler BJ, Kolb A, Nagele T, Schlemmer H-P. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J. Nucl. Med. 2010; 51: 333-336.
132. Büscher K, Judenhofer MS, Kuhlmann MT, Hermann S, Wehrl HF, Schafers KP, Schafers M, Pichler BJ, Stegger L. Isochronous assessment of cardiac metabolism and function in mice using hybrid PET/MRI. J. Nucl. Med. 2010; 51: 1277-1284.
133. 1H-cardiac MRI. Proceedings of the 19th Annual Meeting ISMRM, Montreal, Canada, 2011; 669.
134. Kraitchman DL, Heldman AW, Atalar E, Amado LC, Martin BJ, Pittenger MF, Hare JM, Bulte JW. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 2003; 107: 2290-2293.
135. Naumova AV, Reinecke H, Yarnykh V, Deem J, Yuan C, Murry CE. Ferritin overexpression for noninvasive magnetic resonance imaging-based tracking of stem cells transplanted into the heart. Mol. Imaging 2010; 9: 201-210.
136. Verma DD, Hartner WC, Levchenko TS, Bernstein EA, Torchilin VP. ATP-loaded liposomes effectively protect the myocardium in rabbits with an acute experimental myocardial infarction. Pharmaceut. Res. 2005; 22: 2115-2120.
137. Verma DD, Hartner WC, Thakkar V, Levchenko TS, Torchilin VP. Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction. Pharmaceut. Res. 2007; 24: 2131-2137.
138. Verma DD, Levchenko TS, Bernstein EA, Mongayt D, Torchilin VP. ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model. J. Drug Target. 2006; 14: 273-280.
139. Harel-Adar T, Ben Mordechai T, Amsalem Y, Feinberg MS, Leor J, Cohen S. Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. P. Natl Acad. Sci. USA. 2011; 108: 1827-1832.
140. Leuschner F, Nahrendorf M. Molecular imaging of coronary atherosclerosis and myocardial infarction: considerations for the bench and perspectives for the clinic. Circ. Res. 2011; 108: 593-606.
141. Shellock FG, Spinazzi A. MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. Am. J. Roentgenol. 2008; 191: 1129-1139.
142. Coolen BF, Paulis LEM, Geelen T, Nicolay K, Strijkers GJ. Contrast-enhanced MRI of murine myocardial infarction - Part II. NMR Biomed. 2012; DOI: 10.1002/nbm.2767